Skip to main navigation Skip to search Skip to main content
1990 …2026

Research activity per year

Personal profile

Headline

SENIOR FACULTY Medicine, Hematology and Medical Oncology

Biography

Edward M. Wolin, MD, an internationally-renowned authority on neuroendocrine tumors, is Director of the Center for Carcinoid and Neuroendocrine Tumors and Professor of Medicine, Hematology and Medical Oncology. He is the second director of the Center, which was founded by Richard P. Warner, MD, Professor of Medicine, Gastroenterology. The multi-disciplinary center features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest carcinoid and neuroendocrine tumor programs in the country. Currently, Dr. Wolin serves as Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.

Fingerprint

Dive into the research topics where Edward Wolin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
  • Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)

    Strosberg, J. R., Zemla, T., Geyer, S., Pulsipher, S., Ou, F. S., Behr, S., Raj, N., Vijayvergia, N., Dasari, A., O’Reilly, E. M., Meyerhardt, J. A., Wolin, E. M., Halfdanarson, T. R. & Chan, J. A., Jan 2026, In: Endocrine-Related Cancer. 33, 1, e250415.

    Research output: Contribution to journalArticlepeer-review

    2 Scopus citations
  • Belzutifan for Advanced Pheochromocytoma or Paraganglioma

    LITESPARK-015 Investigators, 20 Nov 2025, In: New England Journal of Medicine. 393, 20, p. 2012-2022 11 p.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    22 Scopus citations
  • Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

    Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., Ou, F. S., Dueck, A. C., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T. R., Konda, B., Trikalinos, N. A., Tawfik, B., Raj, N., Shaheen, S., Vijayvergia, N., Dasari, A. & Strosberg, J. R. & 4 others, Kohn, E. C., Kulke, M. H., O'Reilly, E. M. & Meyerhardt, J. A., 13 Feb 2025, In: New England Journal of Medicine. 392, 7, p. 653-665 13 p.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    145 Scopus citations
  • Neuroendocrine Neoplasms

    Wolin, E. M. & Jensen, R. T., 1 Jan 2023, Goldman-Cecil Medicine, 27th Edition: Volume 1-2. Elsevier, Vol. 2. p. 1561-1568.e1

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    1 Scopus citations
  • Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

    Kulke, M. H., Ou, F. S., Niedzwiecki, D., Huebner, L., Kunz, P., Kennecke, H. F., Wolin, E. M., Chan, J. A., O’Reilly, E. M., Meyerhardt, J. A. & Venook, A., Jun 2022, In: Endocrine-Related Cancer. 29, 6, p. 335-344 10 p.

    Research output: Contribution to journalArticlepeer-review

    Open Access
    17 Scopus citations